Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.
A fully human monoclonal antibody has been isolated that binds toBLyS with high affinity and neutralizes human BLyS bioactivity in vitro and in vivo.
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
In vivo administration of HGS-ETR1 resulted in rapid tumour regression or repression of tumour growth in pre-established colon, non-small-cell lung, and renal tumours in xenograft models, and combined with chemotherapeutic agents resulted in an enhanced antitumour efficacy compared to either agent alone.
BLyS and APRIL Form Biologically Active Heterotrimers That Are Expressed in Patients with Systemic Immune-Based Rheumatic Diseases1
It is shown that APRIL and BLyS can form active heterotrimeric molecules when coexpressed and that circulatingheterotrimers are present in serum samples from patients with systemic immune-based rheumatic diseases.
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of…
It is demonstrated that HGS‐ETR1 and HGS-ETR2 monoclonal antibodies can induce cell death in a variety of cultured and primary lymphoma cells, and may have therapeutic value in lymphoma.
The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS.
Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism
Phage display is used to isolate a substantive panel of fully human anti-TRAIL receptor single chain Fv fragments that have been converted to IgG format and are being studied extensively in clinical trials to investigate their potential utility as human monoclonal antibody therapeutics for the treatment of human cancer.
Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo.
In vivo administration of HGS-ETR2 with or without cross-linker significantly suppressed tumor growth of subcutaneously inoculated human RCC xenografts in immunodeficient mice, suggesting the potential utility of TRAIL-R2 antibody as a novel therapeutic agent in RCC.
Human placenta-derived adherent cells induce tolerogenic immune responses
Modulation of DC differentiation toward immune tolerance as a key mechanism underlying the immunomodulatory activities of PDAC cells is identified.
Enhanced Apoptosis and Tumor Regression Induced by a Direct Agonist Antibody to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor 2
The findings indicate that novel agonist antibody KMTR2 can direct antibody-dependent oligomerization of TRAIL-R2 and initiates efficient apoptotic signaling and tumor regression independent of host effector function, and would be a lead candidate for cancer therapeutics.